- ›
- Tags ›
Life Sciences and Healthcare

How to successfully implement transformative AI technologies and move beyond use case to business value.

As generative AI drives technology into the organizational driver’s seat, how can enterprises practically manage secure implementation while grappling with the big ethical questions?
As GenAI continues to evolve, we can expect even more groundbreaking applications to emerge, offering a promising future for business operations
Discover how GenAI is reshaping IT infrastructure by optimizing data centers, improving cybersecurity, and addressing sustainability challenges amidst rising demand. Read the blog now.
Explore the rise of GenAI, its ethical dilemmas, and why enterprises are adopting private AI for better data security, control and compliance in hybrid cloud environments.
Industry cloud solutions are gaining traction as they offer tailored services for specific industries, enabling faster innovation, regulatory compliance and competitive differentiation for businesses.

AI is transforming the life sciences industry by enhancing data integration, addressing ethical concerns, and ensuring secure, compliant AI applications across the pharma value chain.

It's time to rethink, recreate and revive your working capital strategy to maximize shareholder returns and propel business growth.
The Rate Case Normalizer, powered by GenAI and SAP, automates and streamlines utility rate case processes, reducing preparation time and enhancing accuracy for faster regulatory compliance.
Generative AI, with its ability to generate groundbreaking solutions, is at the forefront of revolutionizing patient-centric supply chains and overcoming existing hurdles of the industry.

Generative AI has transformed software testing, allowing for the automation of tasks like test case creation, synthetic data generation and bug detection.
GenAI plays a crucial role in not just enhancing productivity, it also empowers businesses to reimagine customer engagements, innovate new services and even pioneer novel business models.